{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T12:19:13Z","timestamp":1789820353007,"version":"4.0.1"},"reference-count":12,"publisher":"American Society for Microbiology","issue":"4","license":[{"start":{"date-parts":[[2015,4,1]],"date-time":"2015-04-01T00:00:00Z","timestamp":1427846400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2015,4]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>\n            The novel \u03b2-lactamase inhibitor avibactam is a potent inhibitor of class A, class C, and some class D enzymes. The\n            <jats:italic>in vitro<\/jats:italic>\n            antibacterial activity of the ceftazidime-avibactam combination was determined for a collection of\n            <jats:named-content xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" content-type=\"genus-species\" xlink:type=\"simple\">Enterobacteriaceae<\/jats:named-content>\n            clinical isolates; this collection was enriched for resistant strains, including strains with characterized serine \u03b2-lactamases. The inhibitor was added either at fixed weight ratios to ceftazidime or at fixed concentrations, with the latter type of combination consistently resulting in greater potentiation of antibacterial activity. In the presence of 4 \u03bcg\/ml of avibactam, the ceftazidime MIC\n            <jats:sub>50<\/jats:sub>\n            and MIC\n            <jats:sub>90<\/jats:sub>\n            (0.25 and 2 \u03bcg\/ml, respectively) were both below the CLSI breakpoint for ceftazidime. Further comparisons with reference antimicrobial agents were performed using this fixed inhibitor concentration. Against most ceftazidime-susceptible and -nonsusceptible isolates, the addition of avibactam resulted in a significant increase in ceftazidime activity, with MICs generally reduced 256-fold for extended-spectrum \u03b2-lactamase (ESBL) producers, 8- to 32-fold for CTX-M producers, and &gt;128-fold for KPC producers. Overall, MICs of a ceftazidime-avibactam combination were significantly lower than those of the comparators piperacillin-tazobactam, cefotaxime, ceftriaxone, and cefepime and similar or superior to those of imipenem.\n          <\/jats:p>","DOI":"10.1128\/aac.04218-14","type":"journal-article","created":{"date-parts":[[2015,3,11]],"date-time":"2015-03-11T16:36:49Z","timestamp":1426091809000},"page":"1931-1934","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":55,"title":["<i>In Vitro<\/i>\n            Antibacterial Activity of the Ceftazidime-Avibactam Combination against Enterobacteriaceae, Including Strains with Well-Characterized \u03b2-Lactamases"],"prefix":"10.1128","volume":"59","author":[{"given":"Premavathy","family":"Levasseur","sequence":"first","affiliation":[{"name":"Novexel SA, Romainville, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Marie","family":"Girard","sequence":"additional","affiliation":[{"name":"Novexel SA, Romainville, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Miossec","sequence":"additional","affiliation":[{"name":"Novexel SA, Romainville, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Pace","sequence":"additional","affiliation":[{"name":"Novexel SA, Romainville, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"Coleman","sequence":"additional","affiliation":[{"name":"Novexel SA, Romainville, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.mib.2011.07.026"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkh358"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkp197"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkq306"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2011.09.012"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01722-10"},{"key":"e_1_3_3_8_2","volume-title":"Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard","author":"Clinical Laboratory Standards Institute","year":"2012","unstructured":"Clinical Laboratory Standards Institute. 2012. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard, 9th ed. CLSI, Wayne, PA.","edition":"9"},{"key":"e_1_3_3_9_2","volume-title":"Enterobacteriaceae susceptibility: cephalosporin and carbapenem breakpoint revisions","author":"CLSI","year":"2010","unstructured":"CLSI. 2010. Enterobacteriaceae susceptibility: cephalosporin and carbapenem breakpoint revisions. M100-S20. CLSI, Wayne, PA."},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01512-08"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1574-6968.2001.tb10519.x"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.48.3.1040-1042.2004"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02429-13"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.04218-14","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.04218-14","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T23:04:32Z","timestamp":1645484672000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.04218-14"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,4]]},"references-count":12,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2015,4]]}},"alternative-id":["10.1128\/AAC.04218-14"],"URL":"https:\/\/doi.org\/10.1128\/aac.04218-14","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,4]]},"assertion":[{"value":"2014-09-03","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2015-01-07","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2015-03-11","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}